We caught up with EASD President Prof. Stefano Del Prato (University of Pisa, Italy) to discuss the impact of the COVID-19 pandemic on the diabetes community and the latest emerging therapies in diabetes management.
- What have been the greatest challenges faced by the diabetes community during the COVID-19 pandemic? (0:30)
- What are the most exciting recent/emerging innovations in diabetes therapy? (2:01)
Disclosures: Stefano Del Prato has received grant/research support from AstraZeneca and Boehringer Ingelheim; has served on advisory boards for Applied Therapeutics, AstraZeneca, Boehringer Ingelheim, Eli Lilly and Co, Merck & Co., Novartis Pharmaceuticals, Novo Nordisk and Sanofi; and has received honoraria from AstraZeneca, Boehringer Ingelheim, Eli Lilly and Co, Merck & Co., Novartis Pharmaceuticals, Novo Nordisk, Sanofi, and Takeda Pharmaceuticals.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Share this Video
Related Videos In Diabetes
John Doupis: ADA 83rd Scientific Sessions, 2023: Type 2 diabetes highlights
Dr. John Doupis (Director, Iatriko Paleou Falirou Medical Center, Diabetes Division, Athens, Greece; Editor-in-Chief, touchREVIEWS in Endocrinology) provides his top three highlights from the ADA 83rd Scientific Sessions, 2023 in the field of type 2 diabetes. Disclosures: John Doupis has received consultant fees from Elli Lilly, Novo Nordisk, Abbott, Astra Zeneca and Boehringer Ingelheim. He […]
Chantal Mathieu: ADA 83rd Scientific Sessions, 2023: Research highlights
Prof. Chantal Mathieu (Katholieke Universiteit Leuven, Belgium) provides her highlights from the ADA 83rd Scientific Sessions, 2023 including Teplizumab, an anti-CD3 monoclonal antibody, which was the first disease modifying therapy that delays the progression from stage 2 to stage 3 type 1 diabetes and was FDA approved in November 2022; Orforglipron, an oral, non-peptide glucagon-like […]
Steven Nissen, ADA 2023: Bempedoic acid for cardiovascular disease risk: The CLEAR Outcomes trial
The CLEAR Outcomes trial was a double-blind, randomized, placebo-controlled trial involving patients who were “statin-intolerant” and had, or were at high risk for, cardiovascular disease. The patients were assigned to receive oral bempedoic acid, 180 mg daily, or placebo. Dr. Steven Nissen (Heart, Vascular and Thoracic Institute, Cleveland Clinic Center for Clinical Research, Cleveland, OH, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!